AU2015213778B2 - Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof - Google Patents

Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof Download PDF

Info

Publication number
AU2015213778B2
AU2015213778B2 AU2015213778A AU2015213778A AU2015213778B2 AU 2015213778 B2 AU2015213778 B2 AU 2015213778B2 AU 2015213778 A AU2015213778 A AU 2015213778A AU 2015213778 A AU2015213778 A AU 2015213778A AU 2015213778 B2 AU2015213778 B2 AU 2015213778B2
Authority
AU
Australia
Prior art keywords
isoquinolin
hexahydro
dimethoxy
pyrido
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015213778A
Other languages
English (en)
Other versions
AU2015213778A1 (en
Inventor
Samuel Roger Jesse Hoare
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of AU2015213778A1 publication Critical patent/AU2015213778A1/en
Application granted granted Critical
Publication of AU2015213778B2 publication Critical patent/AU2015213778B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015213778A 2014-02-07 2015-02-06 Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof Active AU2015213778B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461937223P 2014-02-07 2014-02-07
US61/937,223 2014-02-07
PCT/US2015/014893 WO2015120317A1 (en) 2014-02-07 2015-02-06 Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof

Publications (2)

Publication Number Publication Date
AU2015213778A1 AU2015213778A1 (en) 2016-08-18
AU2015213778B2 true AU2015213778B2 (en) 2020-04-23

Family

ID=52589782

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015213778A Active AU2015213778B2 (en) 2014-02-07 2015-02-06 Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof

Country Status (13)

Country Link
US (4) US9782398B2 (enExample)
EP (2) EP3102239A1 (enExample)
JP (4) JP6718376B2 (enExample)
KR (1) KR102328058B1 (enExample)
CN (3) CN106061506A (enExample)
AU (1) AU2015213778B2 (enExample)
CA (1) CA2938581C (enExample)
ES (1) ES3062021T3 (enExample)
IL (1) IL247127B (enExample)
MX (1) MX378664B (enExample)
NZ (2) NZ760790A (enExample)
RU (2) RU2757221C2 (enExample)
WO (1) WO2015120317A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ725826A (en) * 2014-05-06 2023-05-26 Neurocrine Biosciences Inc Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
US9714246B2 (en) * 2015-02-06 2017-07-25 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
RS61645B1 (sr) 2015-10-30 2021-04-29 Neurocrine Biosciences Inc Valbenazin ditozilat i njihovi polimorfi
JP6869988B2 (ja) 2015-12-23 2021-05-12 ニューロクライン バイオサイエンシーズ，インコーポレイテッド （Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法
US10442800B2 (en) 2016-06-29 2019-10-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of NBI-98854, preparation method and use thereof
WO2018102673A1 (en) * 2016-12-02 2018-06-07 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
EP3558276B1 (en) 2016-12-20 2024-11-06 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CA3051830A1 (en) 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
JP7212958B2 (ja) 2017-12-26 2023-01-26 ▲蘇▼州科睿思制▲葯▼有限公司 バルベナジントシル酸塩の結晶形及びその製造方法並びに用途
CA3097189A1 (en) 2018-04-25 2019-10-31 Shinkei Therapeutics Llc Tetrabenazine transdermal delivery device
WO2019212185A1 (ko) * 2018-05-04 2019-11-07 한국원자력의학원 아리피프라졸을 유효성분으로 함유하는 방사선 민감성 증진용 조성물
AU2019287524A1 (en) 2018-06-14 2020-12-24 Neurocrine Biosciences, Inc. VMAT2 inhibitor compounds, compositions, and methods relating thereto
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
MA53239A (fr) * 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
WO2020188551A1 (en) * 2019-03-20 2020-09-24 Bol Pharma Ltd. Methods and compositions for treating autism spectrum disorder and associated disorders
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CA3220946A1 (en) * 2021-06-30 2023-01-05 Angel S. Angelov Valbenazine for use in the add-on treatment of schizophrenia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058261A1 (en) * 2006-11-08 2008-05-15 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
WO2010044981A2 (en) * 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2011019956A2 (en) * 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5777697A (en) * 1980-11-04 1982-05-15 Nippon Zoki Pharmaceut Co Ltd Physiologically active substance nsq
JPS57209225A (en) * 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
US5204329A (en) * 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
WO2000024399A1 (en) * 1998-10-23 2000-05-04 Sepracor Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
NZ566011A (en) * 2005-08-06 2011-01-28 Biovail Lab Internat Barbados Srl 3, 11b cis dihydrotetrabenazine for the treatment of schizophrenia and other psychoses
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
EP3351247A1 (en) * 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058261A1 (en) * 2006-11-08 2008-05-15 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
WO2010044981A2 (en) * 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2011019956A2 (en) * 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"LETTERS Effectiveness of a Clozapine- Aripiprazole Combination in Tourette Syndrome and Bipolar Spectrum Disorder", (2013-01-01), URL: http://neuro.psychiatryonline.org/doi/pdf/10.1176/appi.neuropsych.12020032, (2015-03-24) *
Daniel J Healy ET AL, ELSEVIER Schizophrenia Research, (1997-01-01), pages 259 - 260. *
ITZHAK KIMIAGAR ET AL, JOURNAL OF NEUROLOGY, STEINKOPFF-VERLAG, DA, (2011-11-09), vol. 259, no. 4, doi:10.1007/S00415-011-6235-2, ISSN 1432-1459, pages 660 - 664 *
KOCH H J ET AL, INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, MEDICON INTERNATIONAL, ESHER, GB, (2003-03-01), vol. 57, no. 2, ISSN 1368-5031, pages 147 - 149 *
REMINGTON GARY ET AL, JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, LIPPINCOTT WILLIAMS & WILKINS, US, (2012-02-01), vol. 32, no. 1, doi:10.1097/JCP.0B013E31823F913E, ISSN 0271-0749, pages 95 - 99 *
SPINA E ET AL, INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, CLINICAL NEUROSCIENCE PUBLISHERS, LONDON, GB, (1998-05-01), vol. 13, no. 3, ISSN 0268-1315, pages 141 - 145 *
ZHANG WEI ET AL, NEUROPSYCHOPHARMACOLOGY, ELSEVIER SCIENCE PUBLISHING, NEW YORK, NY, US, (2000-09-01), vol. 23, no. 3, doi:10.1016/S0893-133X(00)00119-6, ISSN 0893-133X, pages 250 - 262 *

Also Published As

Publication number Publication date
JP2017505316A (ja) 2017-02-16
US20160339011A1 (en) 2016-11-24
NZ760790A (en) 2022-11-25
EP4049681B1 (en) 2026-01-07
ES3062021T3 (en) 2026-04-08
IL247127A0 (en) 2016-09-29
RU2016135930A (ru) 2018-03-15
CN106061506A (zh) 2016-10-26
US20200206215A1 (en) 2020-07-02
US20190381029A1 (en) 2019-12-19
AU2015213778A1 (en) 2016-08-18
CN113413385A (zh) 2021-09-21
RU2021128797A (ru) 2021-11-26
RU2016135930A3 (enExample) 2018-10-05
JP6718376B2 (ja) 2020-07-08
WO2015120317A1 (en) 2015-08-13
EP4049681A1 (en) 2022-08-31
EP3102239A1 (en) 2016-12-14
NZ723107A (en) 2022-11-25
JP2019116515A (ja) 2019-07-18
CN113368110A (zh) 2021-09-10
MX2016010071A (es) 2017-04-27
US20180085364A1 (en) 2018-03-29
US9782398B2 (en) 2017-10-10
JP2024003253A (ja) 2024-01-11
IL247127B (en) 2021-04-29
EP4049681C0 (en) 2026-01-07
CA2938581C (en) 2023-02-28
MX378664B (es) 2025-03-10
KR102328058B1 (ko) 2021-11-17
KR20160132830A (ko) 2016-11-21
RU2757221C2 (ru) 2021-10-12
JP2021080294A (ja) 2021-05-27
CA2938581A1 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
AU2015213778B2 (en) Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof
US20190015396A1 (en) Vmat2 inhibitors for treating neurological diseases or disorders
CN101969948B (zh) 用于治疗认知缺损的药盒、组合物、产品或医药
US20150352107A1 (en) Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions
EP2911668A1 (en) Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
US20090306040A1 (en) Mono and Combination Therapy of M1/M4 Agonist (Sabcomeline) for Treatment of Negative Symptoms of Schizophrenia
JP2018076365A (ja) 中枢神経系疾患の治療に有用なトリアゾロ−ピラジン誘導体
WO2007111983A2 (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
JPWO2009069828A1 (ja) パーキンソン病の運動合併症または精神症状を改善する薬剤
HK40079434A (en) Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
HK40062589A (en) Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
RU2508106C2 (ru) Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
US11065232B2 (en) Dihydrotetrabenazine for the treatment of anxiety and psychoses
RU2508096C2 (ru) Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
CN117642160A (zh) 精神药剂及其用途
KR20160143846A (ko) 이명 환자의 치료용 약제
KR20160146872A (ko) 이명 환자의 치료용 약제

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)